Metastatic Adenocarcinoma of Para-urethral Gland Presenting as Inguinal Lymph Node and Recurrent Bulbar Urethral Stricture

Article Sidebar

pdf
Published: Apr 29, 2020
DOI: https://doi.org/10.22374/jeleu.v3i2.84
Keywords:
Para-urethral adenocarcinoma

Main Article Content

Adam Jones
East Lancashire Hospital Trust
Samuel Mills
East Lancashire Hospital Trust
Sinthuja Naguleswaran
East Lancashire Hospital Trust
Tom Newton
Mohan Pillai

Abstract

Para-urethral gland carcinoma is a rare urological malignancy that has a male predominance and has an age-adjusted incidence of 1.5–4.3/million. There are various histological subtypes of para-urethral carcinoma, with adenocarcinoma representing only 16.4% of these. Treatment is dependent on site, stage and patient factors. A multimodal approach is often adopted for the treatment of this malignancy. This includes radical surgery based on site of malignancy and there have been various case reports describing the role of adjuvant chemotherapy. However, there is still no agreed recommendation or available evidence for treatment of this infrequently encountered malignancy. The majority of patients present with symptoms of advanced disease and outcomes remain poor. We report a case of para-urethral gland adenocarcinoma presenting as recurrent bulbar urethral stricture and inguinal lymph node metastasis. This case report aims to highlight the rarity
of the disease and discuss treatment options for this uncommon urological malignancy.

Downloads

Download data is not yet available.

Article Details

How to Cite
Jones, A., Mills, S., Naguleswaran, S., Newton, T., & Pillai, M. (2020). Metastatic Adenocarcinoma of Para-urethral Gland Presenting as Inguinal Lymph Node and Recurrent Bulbar Urethral Stricture. Journal of Endoluminal Endourology, 3(2), e1-e4. https://doi.org/10.22374/jeleu.v3i2.84
Issue
Vol. 3 No. 2 (2020): JELEU
Section
Case Reports
Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Copyright of articles published in all DPG titles is retained by the author(s). The author(s) grants DPG the rights to publish the article and identify itself as the original publisher. The author grants DPG exclusive commercial rights to the article. The author grants any party the rights to use the article freely for non-commercial purposes provided that the original work is properly cited.

Author Biographies

Tom Newton

Consultant Radiologist

Mohan Pillai

Consultant Urologist

References

1. Swartz MA, Porter MP, Lin DW et al. Incidence of pri-mary urethral carcinoma in the United States. Urology 2006;68:1164–68.
2. Gheiler EL, Tefilli MV, Tiguert R et al. Management of primary urethral cancer. Urology 1998;52(3):487–93.
3. Dalbagni G, Zhang ZF, Lacombe L et al. Male urethral carcinoma: analysis of treatment outcome. Urology
1999;53:1126–32.
4. Gupta R, Gupta S, Basu S et al. Primary adenocarcinoma
of the bulbomembranous urethra in a 33-year-old male patient. J Clin Diagnost Res 2017;11:7–8.
5. Stukalin I, Gao Y, Spaner S et al. Primary adenocar-cinoma of bulbomembranous urethra: An exceedingly rare carcinoma in a male patient. Urol Case Rep 2019;26:100941.
6. Venyo A. Clear Cell Adenocarcinoma of the Urethra: Review of the Literature. Int J Surg Oncol 2015;790235
7. GöĞUŞ C, Baltaci S, Orhan D et al. Clear cell adenocar-cinoma of the male urethra. Int J Urol 2003;10:348–9.